This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 03
  • /
  • FDA grants emergency use authorisation for NxTAG C...

FDA grants emergency use authorisation for NxTAG CoV Extended Panel Test for coronavirus.- Luminex Corp

Read time: 1 mins
Published:29th Mar 2020
Luminex Corporation announced that the FDA has issued an Emergency Use Authorization (EUA) for its NxTAG CoV Extended Panel Test. The intended use of this multiplex test is the detection of the SARS-CoV-2 virus. High complexity molecular laboratories can now use the NxTAG test on Luminex's easy-to-use, compact MAGPIX System to rapidly detect the virus that causes COVID-19 disease for up to 96 patients in approximately 4 hours. The MAGPIX System, on which the NxTAG panel runs, utilizes Luminex's unique bead-based chemistry, which makes the system both easy to run and to use. This combination provides a cost-effective testing solution for the rapid delivery of test results.Luminex has developed the NxTAG CoV Extended Panel as a high-throughput, scalable, cost-effective option for detecting SARS-CoV-2. To provide a more complete picture of a patient's respiratory health, the NxTAG CoV Extended Panel can also be run in parallel with the NxTAG Respiratory Pathogen Panel (RPP).
Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights